上客户端，和病友交流
点击下载
返回
肾癌
Ulka Vaishampayan M.D.

Ulka Vaishampayan M.D.

外科
Karmanos cancer center

擅长疾病

临床新药咨询

通过咨询找到适合自己的药物

专家会诊咨询

专业、及时的一对一咨询

如果您的问题未能解决，您还可以选择：

医学顾问

极速问诊

2万名名医
7*24小时为您匹配
1对1

找专家

肿瘤专科专家
对症找医专科专治

专家介绍

2015-06-23 11:031917
 ·         Gender

·         Female

·         Multidisciplinary Team(s)

·         Genitourinary Oncology 
Phase 1 

·         Department/Research Program(s)

·         Department of Oncology 

·         Cancer Type(s)

·         Adrenal Cancer 
Bladder cancer 
Kidney Cancer 
Prostate Cancer 
Testicular Cancer 

·         Contact Info

·         Email:
vaishamu@karmanos.org

·         Education

·         Fellowship
Hematology/oncology Fellowship, Wayne State University, Detroit, MI
Fellowship
Chief Fellow, Hematology/Oncology, Wayne State University, Detroit, MI
Medical School
Byramjee Jeejeebhoy Medical School
Residency
Residency in Medicine, Wayne State University, Detroit, Michigan

·         Professional Memberships/Associations

·         American Society of Clinical Oncology 
Southwest oncology Group 

·         Board Certifications

·         American Board of Medical Oncology

·         Clinical Interests

·         Medical Oncology 

·         Research Interests

·         Reaserch related to clinical trials in prostate, kidney and bladder cancers, overcoming resistance to current therapies and exploring novel treatments and combinations in prostate cancer, as well as development of prognostic and predictive markers in kidney cancer 

·         Profile

·         Dr. Vaishampayan has been providing patient care on staff at Karmanos since 2000. Her experience extends to research, as well as being a member of the editorial board for multiple oncology journal. In addition, she is a lecturer and educator at Wayne State University School of Medicine.

·         Awards

·         Voted one of Best Doctors Inc. 2011-2012 Best Doctors of the Year

·         Publications

·         Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 4;368(14):1314-25 PMID:23550669. Authors: Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, et al.
Phase II trial of satraplatin and bevacizumab in metastatic docetaxel pretreated castrate resistant prostate cancer. Urol Oncol. 2013 Feb 20. S1078-1439. PMID:23433892. Authors: Vaishampayan U, Heilbrun L, Smith D, Baranowski K, Dickow B, Figg W.
External Validation and Comparison with Other Models of the International metastatic Renal-Cell Carcinoma Database Consortium Prognostic Model: A Population-based Study. Lancet oncol 2013 Feb;14(2):141-148. Doi: 10.1016/S1470-2045(12)70559-4. Epub 2013 Jan 98. PMID:23312463. Authors: Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N. Kollmannsberger C, Rini BI, Choueiri TK.
The Association of Clinical Outcome to First-line VEGF-Targeted Therapy with Clinical Outcome to Second-line VEGF-Targeted Therapy in metastatic Renal Cell Carcinoma Patients. For the International mRCC Database Consortium. Target Oncol. 2013 Jan 9. PMID:23300029. Authors: Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, Mackenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, Rha Sy, Donskov FN, North S, Coueiri TK, Heng DY;
Cabozantinib as a Novel Therapy for Renal Cell Carcinoma. Curr oncol Rep. 2013 Jan 5. [Epub ahead of print] PMID:232929795]. Author: Vaishampayan U.

1. 添加医学顾问微信，扫描☟二维码

2. 备注【癌种】进病友群

扫描预约专家问诊

专家科普

同类全球会诊
合作伙伴：